Biocon Pharma receives Health Canada approval for micafungin injection – Business Upturn
Biocon Pharma Limited, a subsidiary of Biocon Limited, has secured approval from Health Canada for its micafungin for injection, USP, available in 50 mg and 100 mg dosages. This approval marks a significant milestone for the company, expanding its portfolio in the biosimilars and generics market. The approved micafungin product is designed for use in adults and children aged four…
Key Insights
- This topic is currently trending
- Experts are closely monitoring developments
- It may impact future decisions
